Drug and Therapeutics Bulletin (DTB) publishes practical, independent, evidence-based information for practising healthcare professionals.

DTB publishes succinct summaries of the best available evidence to enable readers to make informed and unbiased choices regarding medicines and other treatments to help patients get the best care. All content in DTB is commissioned and undergoes a rigorous and transparent editorial process: articles are peer-reviewed externally and internally, authors and DTB Editorial members are required to declare and publish any conflicts of interest.

As a founder member of The International Society of Drug Bulletins, Drug and Therapeutics Bulletin is also completely independent of: the pharmaceutical industry, government and regulatory authorities, advertising and other forms of commercial sponsorship.

Drug and Therapeutics Bulletin is owned by BMJ. For information about the Drug and Therapeutics Bulletin Editor-in-Chief James Cave and his editorial team, please refer to the Editorial Board page.

Submission guidelines

Drug and Therapeutics Bulletin is a commissioned only journal, commissioned authors will be provided with article type specifications and information on how to write and format their article. Commissioned authors should refer to our general formatting guidelines for further support on formatting their article for submission.

For more information about how DTBs editorial processes have changed since its first publication in 1962, please refer to DTB Editorial Processes.


DTB editorials are written by members of DTB’s Editorial Board. Occasionally we will invite guest authors to submit an editorial

DTB select

DTB scans sources of information on treatments, disease management, drug safety and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned. We also include comments on, for example, the strengths of the information, whether it contains anomalies, ambiguities, apparent error or omissions, or whether or how it affects current practice. Each summary is written and peer reviewed by the DTB team.


Topics for DTB review articles are selected by DTB’s editorial board to provide concise overviews of medicines and other treatments to help patients get the best care. Articles are written by a commissioned expert and reviewed externally and internally. Articles include a summary of key points and a brief overview for patients. Articles may also have a series of multiple choice CME questions.

Drug review

DTB drug reviews provide a brief summary of medicines that have been recently launched in the UK and include an overview of the benefits and harms. Articles are prepared by the DTB team and reviewed by members of DTB’s editorial board.

Case report

In conjunction with BMJ Case Reports DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.

Editorial policy

Drug and Therapeutics Bulletin adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria while following guidance produced by bodies that include the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME) and the International Committee of Medical Journal Editors (ICMJE). To view all BMJ Journal policies please refer to the BMJ Author Hub policies page.

We take seriously all possible misconduct. If an Editor, author or reader has concerns that a submitted article describes something that might be considered to constitute misconduct in research, publication or professional behaviour they should forward their concerns to the journal. The publisher will deal with allegations appropriately.

Articles are published under an exclusive licence (or non-exclusive licence for UK Crown and US Federal Government employees) and authors retain copyright. Articles can also be published under a Creative Commons licence to facilitate reuse of the content; please refer to the DTB Copyright Author Licence Statement.

As the author you may wish to post your article in a preprint service, institutional or subject repository, or a scientific social sharing network. For more information on author self-archiving and rights to reuse content – which are dependent on the licence you have obtained – please refer to the BMJ author self-archiving and permissions policies page.

Conflicts of interest

BMJ is committed to ensuring the independence and integrity of our content, products, and services. We strive, therefore, to be transparent about any interests that our users, customers, and partners might want to know about.

In order to maintain its independence, DTB has a strict policy on competing interests. In particular, we need to know if authors have any financial or advisory relationship (paid or unpaid) with the pharmaceutical industry or related healthcare products industry (e.g. medical devices or diagnostics), including the conduct of industry funded clinical trials. Declarations must cover the last three calendar years.

Members of the DTB Editorial Team must be free from conflict of interest with the healthcare industry. We request that our editors fill in a declaration of interest form and this information is updated annually and made publicly available.

Authors are also asked to disclose any competing interests as outlined by the International Committee of Medical Journal Editors uniform declaration of competing interests:

  • Their associations with commercial entities that provided support for the work reported in the submitted manuscript (the time frame for disclosure in this section of the form is the lifespan of the work being reported).
  • Their associations with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript (the time frame for disclosure in this section is the 36 months before submission of the manuscript).
  • Any similar financial associations involving their spouse or their children under 18 years of age.
  • Non-financial associations that may be relevant to the submitted manuscript.

Author COI statements will published as supplementary files with articles along with a summary statement at the beginning of articles.

We also ask reviewers to provide statements of competing interests and we use these when assessing the value of peer review reports. We ask individual reviewers to provide a statement based on BMJ policy at the time they submit their review via our manuscript tracking system.

Peer review

Articles submitted to Drug and Therapeutics Bulletin are subject to peer review. The journal operates single blind peer review whereby the names of the reviewers are hidden from the author; please refer to our peer review guide for more information on what to expect during the peer review process.

DTB requests that all reviewers adhere to a set of basic principles and standards during the peer-review process in research publication; these are based on the COPE Ethical Guidelines for Peer Reviewers. Please refer to our peer review terms and conditions policy page.

BMJ is committed to transparency. Every article we publish includes a description of its provenance (commissioned or not commissioned) and whether it was internally or externally peer reviewed.

Plagiarism is the appropriation of the language, ideas or thoughts of another without crediting their true source and representation of them as one’s own original work. BMJ is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. BMJ runs manuscripts through iThenticate during the peer review process. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting www.ithenticate.com.

Article publishing charges

As a subscription, commissioned only journal there are no submission or publication charges, however authors can choose to have their Review articles published open access for 1,950 GBP or Editorials for 1,000 GBP (exclusive of VAT for UK and EU authors). For more information on open access, funder compliance and institutional programmes please refer to the BMJ Author Hub open access page.

Publication information

Publication Model Subscription
Frequency Monthly
Launch date 1962
Digital Archive LOCKSS
Indexed by MEDLINE (Index Medicus), Scopus, Embase (Excerpta Medica)
Print ISSN 0012-6543
Online ISSN 1755-5248



DTB was a founder member of the International Society of Drug Bulletins (ISDB)

COPE logo

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.


The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

AllTrials logo

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.